Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on May 7, 2025
ImmuneWalk Therapeutics Announces $7 Million Seed Financing and Upcoming Presentations of Positive Clinical Results at Upcoming Medical and Industry Conferences
GlobeNewswire
·
May 7, 2025
Completed seed financing round of $7 million from an institutional investor and ImmuneWalk’s management team Includes oral presentation of positive safety, pharmacokinetic, and pharmacodynamic data from immunology and inflammation (I…
Lithium Argentina Publishes 2024 Sustainability Report
GlobeNewswire
·
May 7, 2025
ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Lithium Argentina AG. (“Lithium Argentina” or the “Company”) (TSX: LAR) (NYSE: LAR) announces the release of its 2024 Sustainability Report, “Lithium With Purpose” (the “Report”). The Report highlights the …
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire
·
May 7, 2025
Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion of patient enrollment and topline results expected Q3 …
Introducing the Wix Model Context Protocol (MCP) Server for Seamless AI-Driven Web App Development
GlobeNewswire
·
May 7, 2025
With Wix MCP Server, users can leverage natural language prompts to seamlessly connect Wix’s comprehensive business functionality with their preferred compatible AI-powered tools, enabling them to build custom experiences on top of Wix or manage their Wix- …
CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
GlobeNewswire
·
May 7, 2025
BERKELEY HEIGHTS, NJ, May 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1- …
Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline
GlobeNewswire
·
May 7, 2025
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical company developing a transformative small molecule platform targeting the intersection of metabolism, immunity, and …
Micropolis Delivers on Vision of Robotics, Artificial Intelligence (AI) and Intelligent Systems at Make it in the Emirates 2025
GlobeNewswire
·
May 7, 2025
DUBAI, May 07, 2025 (GLOBE NEWSWIRE) -- Micropolis Holding Co. (“Micropolis” or the “Company”) (NYSE American: MCRP), a UAE-based pioneering force in robotics, AI, and autonomous mobility, today announced its participation in Make it in the Emirates 2025, …
Alkeus Pharmaceuticals Presents Gildeuretinol Data During the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting May 4-8, 2025
GlobeNewswire
·
May 7, 2025
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced additional data from its Phase 2 clinical study ( …
INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients
GlobeNewswire
·
May 7, 2025
RA'ANANA, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that the INSPIRA™ ART100 has been …
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
GlobeNewswire
·
May 7, 2025
Secured ten new fully-issued patents related to hypertension treatment during last 12 months, bringing global issued patent estate total for this condition to 120 patents Patent estate covering atrioventricular interval modulation (“AVIM”) therapy now …
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
GlobeNewswire
·
May 7, 2025
Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker data Clene collecting NfL …
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments
GlobeNewswire
·
May 7, 2025
Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025; Initiation of VTP-1000 multiple ascending dose expected in the second half of …
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
GlobeNewswire
·
May 7, 2025
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will …
Amerigo Announces Q1-2025 Results & Quarterly Dividend
GlobeNewswire
·
May 7, 2025
Q1-2025 Net Income of $3.3 million Robust EBITDA1 of $15.2 million and Free Cash Flow to Equity1 of $4.8 million 15th Quarterly Dividend of Cdn$.03 Declared $4.6 million Returned through Dividends and Share Buybacks in Q1-2025 VANCOUVER, British Columbia, …
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trials Multiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline …
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
GlobeNewswire
·
May 7, 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody- …
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
GlobeNewswire
·
May 7, 2025
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, …
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
GlobeNewswire
·
May 7, 2025
MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) …
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
GlobeNewswire
·
May 7, 2025
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation …